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Abstract: OBJECTIVES AND METHODS To investigate the impact of prenatal diagnosis on trisomy
21 live births, we collected all prenatal and postnatal trisomy 21 cases (n = 1096) in the eastern half of
Switzerland for the years 1980-1996. RESULTS Despite increasing prenatal detection rates of trisomy 21
foetuses (an increase of 169% in the last 5 versus the first 5 years of the study period) and subsequent
termination of pregnancies, the number of liveborn Down syndrome children remained constant. The
reason is a shift towards a higher mean maternal age from 28 to 30 years between 1980 and 1996. If
mean maternal age at delivery was considered, the observed increase of trisomy 21 conceptions matched
well with the calculated figures. CONCLUSION If the tendency to have pregnancies at a more advanced
age continues and if the use of prenatal diagnosis does not increase, an increase in incidence of Down
syndrome liveborns may be expected in the first decades of the 21st century.






The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Binkert, Franz; Mutter, Michael; Schinzel, Albert (2002). Impact of prenatal diagnosis on the prevalence
of live births with Down syndrome in the eastern half of Switzerland 1980-1996. Swiss Medical Weekly,
132(33-34):478-484.
Impact of prenatal diagnosis on the prevalence
of live births with Down syndrome in the
eastern half of Switzerland 1980–1996
Franz Binkert, Michael Mutter, Albert Schinzel
Institute of Medical Genetics, University of Zurich, Switzerland
Trisomy 21 is the most frequent single chro-
mosome aberration at birth [1]. Free trisomy, i.e.
occurrence of 3 chromosomes 21, comprises about
95% of all trisomies 21 [2, 3] and is due to (mostly
meiotic) nondisjunction occurring predominantly
in the female gamete [4, 5]. The positive correla-
tion between advanced age of the mother at con-
ception and the risk for a Down syndrome child is
well known, although the aetiology is still unclear
[6–12]. Because of this age dependency, the over-
all incidence of newborns with trisomy 21 is mainly
influenced by the maternal age distribution in a
population [13]. However, incidence at birth is
strongly dependent on the proportion of pregnant
women deciding for prenatal diagnosis because of
advanced childbearing age (≥35 years) or abnormal
results of either foetal ultrasound [14–16] or bio-
chemical screening [17, 18] and subsequent termi-
nation of pregnancies with chromosome aberra-
tions.
The issue whether the increasing use of
prenatal diagnosis is dramatically reducing the
number of liveborn children with Down syndrome,
was controversially discussed in Switzerland [19].
Here, in about 10% of all pregnancies, prenatal cy-
togenetic examination is performed [20]. There-
fore we collected all prenatally and postnatally
diagnosed cases with trisomy 21 in the years
1980–1996 in the eastern half of this country.
Switzerland lacks a central registry for birth
defects. However, it is assumed that more or less
all individuals, in whom Down syndrome is sus-
pected, undergo a chromosome examination.
Since the data obtained corresponded well with the
frequencies expected in our population, we could
estimate the influence of prenatal diagnosis on the
incidence of liveborn children with trisomy 21.
Our results are compared with recent trends in
other western countries.
Objectives and Methods: To investigate the im-
pact of prenatal diagnosis on trisomy 21 live births,
we collected all prenatal and postnatal trisomy 21
cases (n = 1096) in the eastern half of Switzerland
for the years 1980–1996. 
Results: Despite increasing prenatal detection
rates of trisomy 21 foetuses (an increase of 169%
in the last 5 versus the first 5 years of the study pe-
riod) and subsequent termination of pregnancies,
the number of liveborn Down syndrome children
remained constant. The reason is a shift towards 
a higher mean maternal age from 28 to 30 years
between 1980 and 1996. If mean maternal age at
delivery was considered, the observed increase of
trisomy 21 conceptions matched well with the
calculated figures. 
Conclusion: If the tendency to have pregnancies
at a more advanced age continues and if the use of
prenatal diagnosis does not increase, an increase in
incidence of Down syndrome liveborns may be ex-
pected in the first decades of the 21st century.
Key words: trisomy 21; Down syndrome; epidemi-
ology; incidence; prenatal diagnosis; trends in incidence







We included all karyotyped trisomy 21 cases (n =
1096), either live- or stillborn or prenatally diagnosed in
the years 1980–1996, whose mothers were living in the
eastern half of Switzerland at the time of birth (cantons of
Appenzell, Aargau, Glarus, Graubünden, Lucerne, Sankt
Gallen, Schaffhausen, Schwyz, Tessin, Thurgau, Unter-
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walden, Uri, Zug, Zurich). In order to obtain complete
data, all other cytogenetic laboratories in Switzerland
were asked to contribute trisomy 21 cases from this area.
The following data were collected for the liveborn: date
of birth and blood sampling, age of the mother, living place
of the mother at birth of the child and karyotype. For the
prenatal cases, date of sampling and material (chorionic
villi, amniocytes, fetal blood), fetal karyotype, month and
year of delivery or of termination of the pregnancy as well
as domicile and age of the mother were collected. The ex-
pected birth date of a foetus was calculated on the basis of
the biparietal diameter or the crown-rump length at the
day at which the foetal sample was collected, or the first
day of the last menstrual period of the mother. Data on
the outcome of the pregnancies were obtained through
questionnaires.
Yearly age distribution of the female population in
every canton of the study area, number of births and age
distribution of the mothers at birth were obtained from
the Federal Office of Statistics at Berne, Switzerland.
Postnatally diagnosed cases of trisomy 21 and prena-
tally diagnosed cases continuing pregnancy to birth sum-
marize to “liveborn observed” and, by dividing this num-
ber by the total number of births, to “incidence observed”.
The impact of prenatal diagnosis on the rate of tri-
somy 21 newborn was estimated by adding all terminated
pregnancies with trisomy 21 foetuses to the liveborn chil-
dren with Down syndrome. Pregnancies with unknown
outcome were considered as terminated to prevent an un-
derestimation of the prenatal contribution to the total
number of trisomy 21 cases.
To evaluate the number of trisomy 21-children that
would have been born in case no prenatal diagnosis had
been performed at all, the trisomy 21 foetuses estimated
to be spontaneously lost during pregnancy had to be de-
duced from the number of liveborn. For this calculation
we used the models of Hook (about 50% probability for a
spontaneous abortion or stillbirth until birth if diagnosed
before the 18th week, and about 35% thereafter [21]) and
Halliday (31% and 18%, respectively [22]). The resulting
numbers were added to the numbers of liveborns with
trisomy 21, giving the “corrected number of liveborn”.
Dividing the latter by the total number of births during
this period resulted in the “corrected incidence”.
Using maternal age specific estimates [8] expected
numbers of newborns with trisomy 21 were calculated.
The comparison between the expected and observed num-
bers of liveborns with Down syndrome revealed whether
or not the ascertainment was complete. 
Changes in the incidence of liveborns with observed
trisomy 21 as well as the use of prenatal diagnosis and their
influence on the frequency of trisomy 21 births were
determined by calculating mean square successive differ-
ences and applying a run-test [23]. Changes in the trend
were verified by the test suggested by Cochran [23].
Results
Prenatal diagnoses
A total of 396 cases of trisomy 21 were detected
prenatally between 1980 and 1996, including 266
through from amniocyte and 130 from chorionic
villus chromosome examination. One hundred and
twenty-one invasive procedures were performed
before the 16th week of pregnancy, and 275 there-
after. Twenty-two of these pregnancies (5.6%)
were carried to term: 6 by decision of the parents
when the diagnosis was made between the 11th and
16thweek of pregnancy, and 16 diagnosed after the
27th week when no termination is performed any-
more. Three hundred and thirty-three foetuses
(84.6%) were aborted. Nine pregnancies (2.3%)
ended as intrauterine foetal death or stillbirth. The
outcome of the pregnancy could not be deter-
mined in 30 cases (7.6%). The proportion in which
a pregnancy with a prenatally detected trisomy 21
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The number of trisomy 21 cases diagnosed
prenatally remained stable during the years
1980–1985, but clearly increased thereafter (figure
1). We analyzed 68 cases during the first five years
of the study, and 183 during the last five years, an
increase of 169%. At birth, 91% of the mothers
were 35 years or older during the first five years.
The absolute number of prenatally diagnosed tri-
somy 21 foetuses from these “old” mothers in-
creased steadily since 1986 and doubled between
1992 and 1996. Mothers of trisomy 21 foetuses
younger than 35 years were rare during the years
1980–1984 (9% of the total); however their pro-
portion increased to 29.5% in 1996.
Postnatal results
A total of 722 liveborns with trisomy 21 were
karyotyped after birth. The absolute numbers fluc-
tuated irregularly with a low of 22 cases in the year
1984 and highs in the years 1989 and 1990 with 57
cases each (fig. 2). Pooling the values over periods
of 5 years, 144 cases were counted between 1980
and 1984, 245 (an increase of 70%) between 1987
and 1991, and 231 in the last 5 years of the study
(60% more than in 1980–1984).
The proportion of the 20–24-year-old moth-
ers among all mothers of a trisomy 21 child di-
minished from 13% in 1980–1984 to 7% between
1992 and 1996. This proportion also decreased
from 27% to 23% in the age group 25–29. How-
ever, it remained similar at 31–33% for the 30–34-
year-old women, and increased from 24 to 30% in
the age group “35 and older”. The incidence of
cytogenetically confirmed liveborn children with
trisomy 21 fluctuated between 0.54 per 1000 live
births (1/1851) in 1984 and 1.32 (1/757) in 1989.
The overall incidence for the years 1980–1996 was
1.00 per 1000 live births.
Proportion of the prenatally diagnosed
trisomies 21
We also noticed changes in the proportion of
the prenatally diagnosed trisomies 21 among all
karyotyped trisomie 21 cases in our series (table 1).
Until 1991, about 1⁄3 were discovered prenatally.
From 1991 to 1996 the proportion increased to
nearly 1⁄2. It stayed constantly high in the age 
group “35 and older”: for the 35–39-year-old
women the value varied between 43 and 63%, for
the age group 40–44 it varied between 75 and 80%,
and for the 44 and older mothers between 80 and
100%. By contrast, in the younger mothers the
percentage increased in the age group 20–24 from
0% in the 1980–1984 period to 11% during
1992–1996, for the age group 25–29 it increased
from 5to 26% throughout the same time, and from
8 to 32% in the 30–34-year old group.
Type of aberration and sex
Three hundred and seventy-four (94.4%) of
the prenatally analysed trisomies 21 and 670
(95.7%) of the postnatally detected cases were free
trisomies; 14 (3.5%) and 12 (1.7%) respectively
were mosaics, and 8 (2.0%) and 18 (2.6%) respec-
tivelywere translocation-trisomies.
Two hundred and twelve (53.5%) of the pre-
natal cases and 365 (52.1%) of the postnatal cases
were males, 183 (46.2%) and 335 (47.9%) respec-
Figure 2
Number of births ob-
served with trisomy






maternal age categories calendar years
(years)
80–84 87–91 92–96
15–19 0.0% 0.0% 0.0%
20–24 0.0% 8.0% 11.1%
25–29 4.9% 15.8% 25.7%
30–34 8.2% 14.9% 32.4%
35–39 51.9% 43.0% 62.8%
40–44 79.5% 76.8% 75.4%
44–49 100.0% 100.0% 83.3%
all ages 32.2% 32.0% 45.5%
Table 1
Prenatally diagnosed
trisomies 21 in pro-
portion of all cytoge-
netically diagnosed
trisomies 21.
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tively were females. The sex of one prenatal case
was not recorded.
Expected trisomies 21
The basis for the calculations were detailed in-
formation on the reproductive female population
(women aged 15 to 49) in our study area and their
births provided by the Federal Office of Statistics
of Switzerland. The number of women at repro-
ductive ages raised continuously from 831 237 in
1980 to 933 237 in 1996. At the beginning of the
nineties, changes in subgroups could be observed:
the group of women aged 20–29 began to decrease
and was outnumbered by the age group 30–39 by
1996. In the year 1980, all women of the whole re-
productive female population gave birth to 39 879
children. This number raised to 45 447 in 1992,
but fell again to 43 558 in 1996. The proportion 
of the mothers between 20 and 24 decreased
throughout the whole study period, the number of
mothers between 25 and 29 increased until the be-
ginning of the nineties, decreasing thereafter. The
proportion of the mothers aged 30 and over in-
creased steadily outnumbering mothers of the
younger age groups in 1996, thus leading to a shift
from mothers in their twenties to mothers in their
thirties. 
Proportion of diagnosed trisomies 21 in the
population and influence of prenatal diagnosis
After correction for prenatal losses, prenatally
diagnosed and subsequently aborted cases were
added to the liveborn, thus determining the inci-
dence of newborn with trisomy 21 if no prenatal
diagnosis would have been performed at all in the
study population. A good match was found for the
expected and effectively karyotyped numbers after
1984 (fig. 3). Using the model of Hook, the birth
rate of trisomy 21 children was diminished by pre-
natal diagnosis by 20% in the period 1987–1991
and by 31% in 1992–1996. The reduction for
mothers aged 40 and over was always high during
those 2 periods: 64 and 60%, respectively, in the
40–44-year-old mothers, as well as 100% and 70%
respectively in the “45 and older” group. In the
younger age groups the impact of prenatal diag-
nosis on the reduction of trisomy 21 live births was
increasing with time. It increased for the age group
35–39 from 29% in the period 1987–1991 to 46%
in 1992–1996, from 9% to 21% for the 30–34-
years-old females and from 6% to 15% for the
25–29 group. For the 20–24-year-old females the
values were 6% and 3%, respectively.
Due to the lower risk estimates of prenatal loss
in the model of Halliday the influence of prenatal
diagnosis is 3.5% to 5% higher than in the model















Prenatally diagnosed trisomies 21
As expected, the number of prenatally diag-
nosed trisomy 21 cases increased from 1986 to
1996 (fig. 1) with significant values (p <0.05 in a
run-test) for the total numbers and the maternal
age groups of 25–29, 30–34 and 35–39 years of age.
It stayed constant from 1980–1985, because at that
time prenatal cytogenetic diagnosis was almost ex-
clusively performed in “older mothers”. Introduc-
tion of chorionic villus sampling [24], ultrasono-
graphic screening (e.g. nuchal translucency [16]) in
the second half of the eighties as well as maternal
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serum screening in the first half of the nineties [18]
successively led to the identification of a 2.5-fold
higher number of trisomy 21 foetuses in the mid-
dle of the nineties versus in the period 1980–1985.
All these additional measurements led to an in-
creased detection rate mainly in mothers aged less
than 35 years.
Parents’ decisions after prenatal diagnosis 
of trisomy 21
Only 9 out of 375 women diagnosed before the
25th week of pregnancy decided to carry their
pregnancy to term. Six foetuses were born. Three
pregnancies ended by intrauterine foetal death.
The other couples decided to terminate the preg-
nancy. The decision is unknown in 30 cases, but
most of them were probably interrupted. The in-
creasing prenatal detection rate of trisomy 21
therefore should have led to a decrease of liveborn
trisomies 21 after 1985, unless other factors would
have counteracted this process.
Liveborn trisomies 21 and proportion 
of prenatally diagnosed trisomies 21
The number of liveborn trisomy 21 children
surprisingly increased between 1980 and 1985 and
leveled off thereafter (fig. 2). Whereas the pro-
portion of the mothers aged 35 and older still
increased slightly from 24 to 30% over the study
period, the proportion of the less than 30 year old
mothers decreased (fig. 4). Nevertheless the pro-
portion of prenatally diagnosed trisomies 21, being
about one third of all diagnosed trisomies 21 in the
eighties, expectably increased thereafter to 40%
and more (fig. 3) due to an increase in the number
of detected foetuses from younger mothers.
Type of aberration and sex
With about 95% of free trisomies and 2.5%
each for mosaics and translocations, the distribu-
tion of the cytogenetic subgroups of Down syn-
drome is in agreement with figures from the liter-
ature as is the sex ratio (53% males and 47% fe-
males) [3, 25].
Expected trisomies 21
Looking at the mothers’ age at birth in the
study area and the number of births between 1980
and 1996, a clear shift from mothers in their twen-
ties to mothers in their thirties (fig. 4) can be rec-
ognized, elevating the peak maternal age at birth
from 26 years in 1980 to 30 years in 1996 (mean
maternal age 28.0 years and 29.84 years respec-
tively). Using the specific age risk ratios by Cuckle
et al. [8], the expected number of Down syndrome
births would have increased through this shift from
about 1.42/1000 in 1980 to 1.68/1000 in 1996, if
no prenatal diagnosis with subsequent abortion
would have been performed at all.
Proportion of diagnosed trisomies 21
Using the models of Hook et al. [21] and Hal-
liday et al. [22], the evaluation of our data shows a
complete ascertainment for the years 1985 and
later. A detailed analysis of the earlier results in-
dicated a deficit of cases in some cantons. This is
most likely due to incomplete cytogenetic ascer-
tainment of clinically diagnosed cases of Down
syndrome. Not considering the possibility of
familial translocation-trisomies, many physicians
considered cytogenetic confirmation to be unnec-
essary if the phenotype was classical of Down
syndrome. 
Applying the model of Hook, the birth rate of
Down syndrome children was reduced by prenatal
diagnosis by about 20% (mainly due to the age
indication) in the early eighties. The reduction
increased to about 31% in the period 1992–1996,
because of the introduction of more thorough
ultrasound examinations, of the improvement of
the skill of the examiners, and of maternal serum
screening, all of which mainly affected women less
Figure 4
Age of the mothers 
at birth in the years
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than 35 years of age. Because of lower estimates of
prenatal losses, these values are slightly higher (3.5
to 5%) using the model of Halliday. However, due
to the shift to higher maternal ages at conception
over the years with a consequently higher proba-
bility of trisomic foetuses, all these measurements
could only counterbalance an increase of the num-
ber of Down syndrome newborns.
Comparison with the literature
Several authors stated that the incidence of
liveborns with Down syndrome stayed constant or
even slightly increased since the mid-eighties even
in countries with increasing numbers of prenatal
diagnoses. The cause is an increase of the mean
maternal age at birth and the rising proportion of
mothers aged more than 35 years in many western
countries since the mid-seventies [26–40]. This
latter proportion was about 15% in Switzerland in
1996 [20]. As in other industrialized countries,
women born during the period of the baby boom
after the second world war (1945–1963) started to
dominate in Switzerland among pregnant women
in the nineties. As a consequence of reduced birth
rates due to oral contraception, they overruled in
numbers the women under 30 [34, 38, 41]. These
facts and the tendency to postpone family planning
should dramatically increase the incidence of live-
born children with Down syndrome (30–35, 37,
38, 41]. In our study area, the increase was from
1.42/1000 in 1980 to 1.68/1000 in 1996. Accord-
ing to different calculations [38, 41] this increase
will continue in the first decade of the new Mil-
lennium. Cornel et al. [38] predicted an incidence
of 2.2/1000 for the year 2001 in the Netherlands
without prenatal diagnosis and selective abortion.
Similar trends are expected in Switzerland due to
comparable demographic and lifestyle conditions.
Only two studies showed a reduction of Down
syndrome birth rates due to increased use of ma-
ternal serum screening: a Scottish investigation
[42] showing a decrease of the incidence from
1.08/1000 in 1990–1991 to 0.77/1000 in 1992–
1994, and a Wallonian study [43] revealing a de-
crease from 0.95/1000 in 1984–1983 to 0.66/1000
in 1993–1998.
Although 65 to 75% of the trisomy 21 con-
ceptions of mothers aged 35 and over were pre-
natally diagnosed between 1992 and 1996 in our
study area, the total incidence of liveborn trisomy
21 children decreased only by 30–36%, because
85% of all children and 70% of all children with
trisomy 21 are still born to mothers aged less than
35 years at delivery. Because the mean maternal
age at birth is increasing, only better risk stratifi-
cation and discovery of yet unknown risk factors in
younger women could counterbalance an increase
[33, 38, 44]. A change could be reached by more
frequent use of the maternal serum screening [20].
As the life expectancy of newborns with Down
syndrome increased since the fifties [45–47] a
higher prevalence of individuals with Down syn-
drome is expected in the first decade of the 21st
century in Switzerland as well as in most other
countries in Western Europe.
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